Replies to post #150443 on Biotech Values

[DewDiligence]

ApoE+ is not a factor in these trials.

Isn’t this decision a consequence of the Bapineuzumab results?

[genisi]

I think bapineuzumab is out of the game and my guess is ADCS scientists await for the biomarkers data from solanezumab EXPEDITION trials and if correlate with cognitive/functional findings, it will be the one cause as you've said safety is very important here and solanezumab has more safety data which are good.